Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Monique Roobol

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Prostatic Neoplasms

Chemicals & Drugs

Procedures

Concepts & Ideas

Geographic Areas

Anatomy

Prostate

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Roobol Monique J; Schröder Fritz H; Crawford E David; Freedland Stephen J; Sartor A Oliver; Fleshner Neil; Andriole Gerald L
A framework for the identification of men at increased risk for prostate cancer.
van den Bergh Roderick C N; Essink-Bot Marie-Louise; Roobol Monique J; Wolters Tineke; Schröder Fritz H; Bangma Chris H; Steyerberg Ewout W
Anxiety and distress during active surveillance for early prostate cancer.
Bangma Chris H; Roobol Monique J; Steyerberg Ewout W
Predictive models in diagnosing indolent cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Monique Roobol (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Roobol Monique J; Schröder Fritz H; Crawford E David; Freedland Stephen J; Sartor A Oliver; Fleshner Neil; Andriole Gerald L
A framework for the identification of men at increased risk for prostate cancer.
The Journal of urology 2009;182(5):2112-20.
2009: van den Bergh Roderick C N; Essink-Bot Marie-Louise; Roobol Monique J; Wolters Tineke; Schröder Fritz H; Bangma Chris H; Steyerberg Ewout W
Anxiety and distress during active surveillance for early prostate cancer.
Cancer 2009;115(17):3868-78.
2009: Bangma Chris H; Roobol Monique J; Steyerberg Ewout W
Predictive models in diagnosing indolent cancer.
Cancer 2009;115(13 Suppl):3100-6.
2009: Roobol Monique J
Words of wisdom. Re: Mortality results from a randomized prostate- cancer screening Trial.
European urology 2009;55(6):1481-2.
2009: van den Bergh Roderick C N; Roemeling Stijn; Roobol Monique J; Aus Gunnar; Hugosson Jonas; Rannikko Antti S; Tammela Teuvo L; Bangma Chris H; Schröder Fritz H
Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
BJU international 2009;103(11):1472-7.
2009: Schröder Fritz H; Roobol Monique J
Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
Current opinion in urology 2009;19(3):227-31.
2009: Schröder Fritz H; Hugosson Jonas; Roobol Monique J; Tammela Teuvo L J; Ciatto Stefano; Nelen Vera; Kwiatkowski Maciej; Lujan Marcos; Lilja Hans; Zappa Marco; Denis Louis J; Recker Franz; Berenguer Antonio; Määttänen Liisa; Bangma Chris H; Aus Gunnar; Villers Arnauld; Rebillard Xavier; van der Kwast Theodorus; Blijenberg Bert G; Moss Sue M; de Koning Harry J; Auvinen Anssi;
Screening and prostate-cancer mortality in a randomized European study.
The New England journal of medicine 2009;360(13):1320-8.
2009: Jansen Flip H; Roobol Monique; Jenster Guido; Schröder Fritz H; Bangma Chris H
Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
European urology 2009;55(3):563-74.
2009: Korfage Ida J; Pluijm Saskia; Roobol Monique; Dohle Gert R; Schröder Fritz H; Essink-Bot Marie-Louise
Erectile dysfunction and mental health in a general population of older men.
The journal of sexual medicine 2009;6(2):505-12.
2009: Wolters Tineke; Roobol Monique J; Bangma Chris H; Schröder Fritz H
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
European urology 2009;55(2):385-92.
2009: Schröder Fritz H; Roobol Monique J
Re: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
BJU international 2009;103(2):143-4.
2008: Jansen F H; Roobol M; Bangma C H; van Schaik R H N
Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection.
Clinical chemistry 2008;54(12):1999-2006.
2008: van den Bergh Roderick C N; Roobol Monique J; Wolters Tineke; van Leeuwen Pim J; Schröder Fritz H
The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.
BJU international 2008;102(9):1068-73.
2008: Roobol Monique J
Algorithms, nomograms and the detection of indolent prostate cancer.
World journal of urology 2008;26(5):423-9.
2008: van den Bergh Roderick C N; Roemeling Stijn; Roobol Monique J; Wolters Tineke; Schröder Fritz H; Bangma Chris H
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
European urology 2008;54(3):505-16.
2008: Gosselaar Claartje; Roobol Monique J; Roemeling Stijn; Schröder Fritz H
The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
European urology 2008;54(3):581-8.
2008: Korfage Ida J; Roobol Monique; de Koning Harry J; Kirkels Wim J; Schröder Fritz H; Essink-Bot Marie-Louise
Does "normal" aging imply urinary, bowel, and erectile dysfunction? A general population survey.
Urology 2008;72(1):3-9.
2008: Gosselaar C; Kranse R; Roobol M J; Roemeling S; Schröder F H
The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.
The Prostate 2008;68(9):985-93.
2008: Schröder Fritz H; Bangma Chris H; Roobol Monique J
Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
European urology 2008;53(5):901-8.
2008: Roobol Monique
(I) Re: prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
European urology 2008;53(4):852-4; discussion 854-5.
2008: Gosselaar Claartje; Roobol Monique J; Roemeling Stijn; Wolters Tineke; van Leenders Geert J L H; Schröder Fritz H
The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer.
BJU international 2008;101(6):685-90.
2008: Schröder Fritz H; Carter H Ballentine; Wolters Tineke; van den Bergh Roderick C N; Gosselaar Claartje; Bangma Chris H; Roobol Monique J
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics.
European urology 2008;53(3):468-77.
2008: Roobol Monique J; Schröder Fritz H
Re: Is a screening interval of every 4 years for prostate cancer acceptable?
Journal of the National Cancer Institute 2008;100(3):222; author reply 223-4.
2008: Wolters Tineke; Roobol Monique J; Schröder Fritz H; van der Kwast Theodorus H; Roemeling Stijn; van der Cruijsen-Koeter Ingrid W; Bangma Chris H; van Leenders Geert J L H;
Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?
BJU international 2008;101(3):283-8.
2007: van den Bergh Roderick C N; Roemeling Stijn; Roobol Monique J; Roobol Wouter; Schröder Fritz H; Bangma Chris H
Prospective validation of active surveillance in prostate cancer: the PRIAS study.
European urology 2007;52(6):1560-3.
2007: Roemeling Stijn; Roobol Monique J; Kattan Michael W; van der Kwast Theo H; Steyerberg Ewout W; Schröder Fritz H
Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations.
Cancer 2007;110(10):2218-21.
2007: Bangma Christiaan H; Roobol Monique J
How common is PSA screening in elderly men with limited life expectancies?
Nature clinical practice. Urology 2007;4(10):532-3.
2007: Schröder Fritz H; Roobol Monique J
Words of wisdom. Re: prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
European urology 2007;52(3):921.
2007: Roobol Monique J; Grenabo Anna; Schröder Fritz H; Hugosson Jonas
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Journal of the National Cancer Institute 2007;99(17):1296-303.
2007: Roemeling Stijn; Roobol Monique J; Otto Suzie J; Habbema Dik F; Gosselaar Claartje; Lous Jan J; Cuzick Jack; Schröder Fritz H
Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial.
The Prostate 2007;67(10):1053-60.
2007: Postma Renske; Schröder Fritz H; van Leenders Geert J L H; Hoedemaeker Robert F; Vis Andre N; Roobol Monique J; van der Kwast Theodorus H
Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
European urology 2007;52(1):89-97.
2007: Roobol Monique J
Re: Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
European urology 2007;51(5):1441-2.
2007: Roemeling Stijn; Roobol Monique J; de Vries Stijn H; Wolters Tineke; Gosselaar Claartje; van Leenders Geert J L H; Schröder Fritz H
Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.
European urology 2007;51(5):1244-50; discussion 1251.
2007: Roobol M J; Zappa M; Määttänen L; Ciatto S
The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
The Prostate 2007;67(4):439-46.
2007: Schröder Fritz H; Habbema Dik F; Roobol Monique J; Bangma Chris H
Prostate cancer in the Swedish section of ERSPC--evidence for less metastases at diagnosis but not for mortality reduction.
European urology 2007;51(3):588-90.
2007: Gosselaar Claartje; Roobol Monique J; Roemeling Stijn; van der Kwast Theo H; Schröder Fritz H
Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
The Prostate 2007;67(2):154-61.
2007: Steyerberg E W; Roobol M J; Kattan M W; van der Kwast T H; de Koning H J; Schröder F H
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
The Journal of urology 2007;177(1):107-12; discussion 112.
2006: van der Cruijsen-Koeter Ingrid W; Roobol Monique J; Wildhagen Mark F; van der Kwast T H; Kirkels W J; Schröder Fritz H
Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
Urology 2006;68(3):615-20.
2006: Roobol M J
The use of nomograms in the detection of prostate cancer.
The Prostate 2006;66(12):1266-7.
2006: Roemeling Stijn; Roobol Monique J; Postma Renske; Gosselaar Claartje; van der Kwast Theo H; Bangma Chris H; Schröder Fritz H
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
European urology 2006;50(3):475-82.
2006: Roemeling Stijn; Roobol Monique J; Gosselaar Claartje; Schröder Fritz H
Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
The Prostate 2006;66(10):1076-81.
2006: Postma Renske; van Leenders Arno G J L H; Roobol Monique J; Schröder Fritz H; van der Kwast Theodorus H
Tumour features in the control and screening arm of a randomized trial of prostate cancer.
European urology 2006;50(1):70-5.
2006: Roobol Monique J; Schröder Fritz H; Kranse Ries;
A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam).
The Prostate 2006;66(6):604-12.
2006: Gosselaar Claartje; Roobol Monique J; Roemeling Stijn; de Vries Stijn H; Cruijsen-Koeter Ingrid van der; van der Kwast Theo H; Schröder Fritz H;
Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
The Prostate 2006;66(6):625-31.
2006: van der Kwast Theodorus H; Ciatto Stefano; Martikainen Paula M; Hoedemaeker Robert; Laurila Marita; Pihl Carl-Gustaph; Hugosson Jonas; Neetens Ingrid; Nelen Vera; Di Lollo Simonetta; Roobol Monique J; Määtänen Liisa; Santonja Carlos; Moss Sue; Schröder Fritz H
Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.
International journal of cancer. Journal international du cancer 2006;118(10):2538-42.
2006: Roemeling Stijn; Roobol Monique J; de Vries Stijn H; Gosselaar Claartje; van der Kwast Theo H; Schröder Fritz H
Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population.
The Journal of urology 2006;175(4):1332-6.
2006: Schröder Fritz H; Roobol Monique J; van der Kwast Theo H; Kranse Ries; Bangma Chris H
Does PSA velocity predict prostate cancer in pre-screened populations?
European urology 2006;49(3):460-5; discussion 465.
2006: Korfage Ida J; de Koning Harry J; Roobol Monique; Schröder Fritz H; Essink-Bot Marie-Louise
Prostate cancer diagnosis: the impact on patients' mental health.
European journal of cancer (Oxford, England : 1990) 2006;42(2):165-70.
2005: Schröder Fritz H; Roobol Monique J; Boevé Egbert R; de Mutsert Reneé; Zuijdgeest-van Leeuwen Sonja D; Kersten I; Wildhagen Mark F; van Helvoort Ardy
Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
European urology 2005;48(6):922-30; discussion 930-1.
2005: Schröder Fritz H; Raaijmakers René; Postma Renske; van der Kwast Theo H; Roobol Monique J
4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
The Journal of urology 2005;174(2):489-94; discussion 493-4.
2005: van der Cruijsen-Koeter Ingrid W; Vis André N; Roobol Monique J; Wildhagen Mark F; de Koning Harry J; van der Kwast Theo H; Schröder Fritz H
Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.
The Journal of urology 2005;174(1):121-5.
2005: Schröder Fritz H; Roobol Monique J; Damhuis Ronald A M; de Koning Harry J; Blijenberg Bert G; Van der Kwast Theo H; Kirkels Wim J; Bangma Chris H
Rotterdam randomized pilot studies of screening for prostate cancer--an overview after 10 years.
Journal of the National Cancer Institute 2005;97(9):696.
2005: Roobol Monique J; Roobol Dina W; Schröder Fritz H
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Urology 2005;65(2):343-6.
2005: Gosselaar Claartje; Roobol Monique J; Schröder Fritz H
Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
BJU international 2005;95(2):231-7.
2005: Postma Rensbe; de Vries Shijn H; Roobol Monique J; Wildhagen Mark F; Schröder Fritz H; van der Kwast Theo H
Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
Cancer 2005;103(4):708-16.
2005: Ito Kazuto; Raaijmakers René; Roobol Monique; Wildhagen Mark; Yamanaka Hidetoshi; Schröder Fritz H
Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Cancer 2005;103(2):242-50.
2004: Postma Renske; Roobol Monique; Schröder Fritz H; van der Kwast Theodorus H
Lesions predictive for prostate cancer in a screened population: first and second screening round findings.
The Prostate 2004;61(3):260-6.
2004: Janssen J A M J L; Wildhagen M F; Ito K; Blijenberg B G; Van Schaik R H N; Roobol M J; Pols H A P; Lamberts S W J; Schröder F H
Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
The Journal of clinical endocrinology and metabolism 2004;89(9):4391-6.
2004: Schröder Fritz H; Roobol Monique J
Detection characteristics in randomized prostate screening.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5641-2.
2004: Raaijmakers Rene; Blijenberg Bert G; Finlay Judith A; Rittenhouse Harry G; Wildhagen Mark F; Roobol Monique J; Schröder Fritz H
Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.
The Journal of urology 2004;171(6 Pt 1):2245-9.
2004: Roobol M J; van der Cruijsen I W; Schröder F H
No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Urology 2004;63(5):892-7; discussion 897-9.
2004: Postma Renske; Roobol Monique; Schröder Fritz H; van der Kwast Theodorus H
Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
Cancer 2004;100(5):968-75.
2004: Raaijmakers René; Wildhagen Mark F; Ito Kazuto; Pàez Alvaro; de Vries Stijn H; Roobol Monique J; Schröder Fritz H
Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Urology 2004;63(2):316-20.
2004: Roobol M J; Kranse R; de Koning H J; Schröder F H
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Urology 2004;63(2):309-13; discussion 313-5.
2003: Van der Kwast T H; Roobol M J; Wildhagen M F; Martikainen P M; Määtänen L; Pihl C G; Santonja C; Bubendorf L; Neetens I; Di Lollo S; Hoedemaeker R F
Consistency of prostate cancer grading results in screened populations across Europe.
BJU international 2003;92 Suppl 2():88-91.
2003: Roobol M J; Kirkels W J; Schröder F H
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).
BJU international 2003;92 Suppl 2():48-54.
2003: Schröder F H; Denis L J; Roobol M; Nelen V; Auvinen A; Tammela T; Villers A; Rebillard X; Ciatto S; Zappa M; Berenguer A; Paez A; Hugosson J; Lodding P; Recker F; Kwiatkowski M; Kirkels W J;
The story of the European Randomized Study of Screening for Prostate Cancer.
BJU international 2003;92 Suppl 2():1-13.
2002: Raaijmakers René; Kirkels Wim J; Roobol Monique J; Wildhagen Mark F; Schrder Fritz H
Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.
Urology 2002;60(5):826-30.
2002: Vis A N; Kranse R; Roobol M; van der Kwast Th H; Schröder F H
Serendipity in detecting disease in low prostate-specific antigen ranges.
BJU international 2002;89(4):384-9.
2002: Roobol Monique J; Kranse Ries; van der Cruijsen Ingrid W; Schröder Fritz H
A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate.
Urology 2002;59(1):91-6.
2001: Vis A N; Hoedemaeker R F; Roobol M; Schröder F H; van der Kwast T H
The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer.
Cancer 2001;92(3):524-34.
2001: Hoedemaeker R F; van der Kwast T H; Boer R; de Koning H J; Roobol M; Vis A N; Schröder F H
Pathologic features of prostate cancer found at population-based screening with a four-year interval.
Journal of the National Cancer Institute 2001;93(15):1153-8.
2001: Vis A N; Hoedemaeker R F; Roobol M; van der Kwast T H; Schröder F H
Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).
The Prostate 2001;47(4):252-61.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Monique Roobol

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Geographic Areas

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Monique Roobol (preview)

All Publications